Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 16/20 | 0.52 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 5/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17630550 | 1.00 | TBK1 (0.52) | TBK1IKBKEUSP30JAK2GPR119 | |
| SCHEMBL16853884 | 1.00 | TBK1 (0.52) | TBK1IKBKEUSP30JAK2GPR119 | |
| SCHEMBL17631334 | 1.00 | TBK1 (0.52) | TBK1IKBKEUSP30JAK2GPR119 | |
| SCHEMBL18348317 | 0.86 | TBK1 (0.52) | TBK1IKBKEUSP30GPR119PDE4B | |
| SCHEMBL16828572 | 0.86 | TBK1 (0.44) | TBK1JAK2 | |
| SCHEMBL16828738 | 0.86 | TBK1 (0.44) | TBK1JAK2 | |
| SCHEMBL1667168 | 0.84 | GPR119 (0.55) | TBK1IKBKEGPR119PDE4B | |
| SCHEMBL17645231 | 0.84 | TBK1 (0.42) | TBK1IKBKEUSP30JAK2GPR119 | |
| SCHEMBL17631219 | 0.84 | GPR119 (0.43) | TBK1IKBKEUSP30GPR119 | |
| SCHEMBL17631222 | 0.84 | GPR119 (0.43) | TBK1IKBKEUSP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (UK) | 2017-10-26 | — | — | US | disclosed |
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (UK) | 2017-10-26 | — | — | US | disclosed |
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (UK) | 2017-10-26 | — | — | US | disclosed |
| WO-2015092610-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | TNNI3, MUSK, MYLK2 | TBK1 1795/4885IKBKE 667/4885USP30 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.